{
  "abstract": "Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse Event Reporting System (2017–2024), we evaluated formulation- and sex-specific associations. Among 31 774 semaglutide cases, Wegovy demonstrated the strongest signal for ION (reporting odds ratio (ROR)=74.89) compared with Ozempic (ROR=18.81). Sex-stratified analyses showed higher odds in men (ROR=116.37), and multivariable regression confirmed greater risk with Wegovy versus Ozempic (adjusted OR (AOR)=4.74) and in men versus women (AOR=3.33). These findings highlight a potential dose-dependent safety concern that warrants urgent prospective evaluation to guide prescribing and regulatory policy.",
  "authors": [
    {
      "affiliations": [
        "Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"
      ],
      "name": "Moiz Lakhani"
    },
    {
      "affiliations": [
        "Department of Surgery, Section of Ophthalmology, University of Calgary, Calgary, Alberta, Canada"
      ],
      "name": "Abdullah Al-Ani"
    },
    {
      "affiliations": [
        "Department of Ophthalmology and Visual Sciences, University of Toronto, Toronto, Ontario, Canada"
      ],
      "name": "Marko Popovic"
    },
    {
      "affiliations": [
        "Department of Surgery, Section of Ophthalmology, University of Calgary, Calgary, Alberta, Canada"
      ],
      "name": "Étienne Bénard-Séguin"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada"
      ],
      "name": "Edward Margolin"
    }
  ],
  "title": "Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk",
  "uid": "9f00f108-f9aa-52bc-9975-f682290fc30b"
}